All In MedTech

FDA Clearance Tracker · P030030-S001

TEGRESS URETHRAL IMPLANT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 9, 2005 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P030030-S001
Device name
TEGRESS URETHRAL IMPLANT
Applicant location
Covington, GA
Received
Jan 28, 2005
Decided
Feb 9, 2005
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P030030

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MODIFICATION OF THE LABELING TO REFLECT A NEW DEVICE TRADE NAME. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME TEGRESS URETHRAL IMPLANT AND IS INDICATED FOR TRANSURETHRAL INJECTION IN THE TREATMENT OF ADULT WOMEN DIAGNOSED WITH STRESS URINARY INCONTINENCE (SUI) DUE TO INTRINSIC SPHINCTER DEFICIENCY (ISD).

Source documents

Other decisions for C.R. Bard, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.